Development of drug resistance is the main reason for low chemotherapy effectiveness in treating ovarian cancer. Paclitaxel (PAC) is a chemotherapeutic drug used in the treatment of this cancer. We analysed the development of PAC resistance in two ovarian cancer cell lines. Exposure of drug-sensitive cell lines (A2780 and W1) to PAC was used to determine the primary response. An established response was determined in PAC-resistant sublines of the A2780 and W1 cell lines. qRT-PCR was performed to measure the expression levels of specific genes. We observed decreased expression of the PCDH9, NSBP1, MCTP1 and SEMA3A genes in the PAC-resistant cell lines. Short-term exposure to PAC led to increased expression of the MDR1 and BCRP genes in the A...
Debulking surgery followed by chemotherapy are the standard of care for high-grade serous carcinoma....
BACKGROUND Although paclitaxel is used for hormone-resistant prostate cancer, relapse definitely oc...
Ovarian cancer is the most lethal of all gynecological malignancies, and exhibit an overall fiveyear...
Development of drug resistance is the main reason for low chemotherapy effectiveness in treating ova...
Low efficiency of chemotherapy in ovarian cancer results from the development of drug resistance. Ci...
Paclitaxel (PTX) is a potent anti-neoplastic agent that is highly effective in treating ovarian canc...
BackgroundOvarian cancer is the leading gynecologic cancer diagnosed in North America and because re...
Abstract Background Ovarian cancer is the leading gynecologic cancer diagnosed in North America and ...
Epithelial ovarian cancer (EOC) is a lethal gynecological cancer, of which paclitaxel resistance is ...
The majority of ovarian tumors eventually recur in a drug resistant form. Using cisplatin sensitive ...
Background Chemotherapy resistance remains a major obstacle in the treatment of women with ovarian c...
The aim of the study is to review the mechanisms of resistance to four classes of drugs that are wid...
Despite the use of front-line anticancer drugs such as paclitaxel for ovarian cancer treatment, mort...
OBJECTIVE To study the differential expression of COP9, JAK2, HSPS and NADH genes and their relation...
SummaryCytotoxic drug resistance is a major cause of cancer treatment failure. We report an RNA inte...
Debulking surgery followed by chemotherapy are the standard of care for high-grade serous carcinoma....
BACKGROUND Although paclitaxel is used for hormone-resistant prostate cancer, relapse definitely oc...
Ovarian cancer is the most lethal of all gynecological malignancies, and exhibit an overall fiveyear...
Development of drug resistance is the main reason for low chemotherapy effectiveness in treating ova...
Low efficiency of chemotherapy in ovarian cancer results from the development of drug resistance. Ci...
Paclitaxel (PTX) is a potent anti-neoplastic agent that is highly effective in treating ovarian canc...
BackgroundOvarian cancer is the leading gynecologic cancer diagnosed in North America and because re...
Abstract Background Ovarian cancer is the leading gynecologic cancer diagnosed in North America and ...
Epithelial ovarian cancer (EOC) is a lethal gynecological cancer, of which paclitaxel resistance is ...
The majority of ovarian tumors eventually recur in a drug resistant form. Using cisplatin sensitive ...
Background Chemotherapy resistance remains a major obstacle in the treatment of women with ovarian c...
The aim of the study is to review the mechanisms of resistance to four classes of drugs that are wid...
Despite the use of front-line anticancer drugs such as paclitaxel for ovarian cancer treatment, mort...
OBJECTIVE To study the differential expression of COP9, JAK2, HSPS and NADH genes and their relation...
SummaryCytotoxic drug resistance is a major cause of cancer treatment failure. We report an RNA inte...
Debulking surgery followed by chemotherapy are the standard of care for high-grade serous carcinoma....
BACKGROUND Although paclitaxel is used for hormone-resistant prostate cancer, relapse definitely oc...
Ovarian cancer is the most lethal of all gynecological malignancies, and exhibit an overall fiveyear...